Next Article in Journal
Glycyrrhizic Acid Can Attenuate Metabolic Deviations Caused by a High-Sucrose Diet without Causing Water Retention in Male Sprague-Dawley Rats
Next Article in Special Issue
The Role of n-3 Polyunsaturated Fatty Acids in the Prevention and Treatment of Breast Cancer
Previous Article in Journal
The Health Advantage of a Vegan Diet: Exploring the Gut Microbiota Connection
Previous Article in Special Issue
n-3 Polyunsaturated Fatty Acids and Mechanisms to Mitigate Inflammatory Paracrine Signaling in Obesity-Associated Breast Cancer
Article Menu

Export Article

Open AccessArticle
Nutrients 2014, 6(11), 4839-4855; doi:10.3390/nu6114839

The Anti-Proliferative Effects of Enterolactone in Prostate Cancer Cells: Evidence for the Role of DNA Licencing Genes, mi-R106b Cluster Expression, and PTEN Dosage

1
Food Nutrition & Health, Food and Bio-based Products, AgResearch Grasslands Research Centre, Palmerston North 4442, New Zealand
2
Gravida: National Centre for Growth and Development, The University of Auckland, Auckland 1142, New Zealand
3
Department of Food and Nutritional Sciences, P.O. Box 226, Whiteknights, Reading RG6 6AP, UK
4
The Riddet Institute, Massey University, Palmerston North 4442, New Zealand
*
Author to whom correspondence should be addressed.
Received: 1 September 2014 / Revised: 10 October 2014 / Accepted: 20 October 2014 / Published: 3 November 2014
(This article belongs to the Special Issue Nutrition and Cancer)
View Full-Text   |   Download PDF [876 KB, uploaded 3 November 2014]   |  

Abstract

The mammalian lignan, enterolactone, has been shown to reduce the proliferation of the earlier stages of prostate cancer at physiological concentrations in vitro. However, efficacy in the later stages of the disease occurs at concentrations difficult to achieve through dietary modification. We have therefore investigated what concentration(s) of enterolactone can restrict proliferation in multiple stages of prostate cancer using an in vitro model system of prostate disease. We determined that enterolactone at 20 μM significantly restricted the proliferation of mid and late stage models of prostate disease. These effects were strongly associated with changes in the expression of the DNA licencing genes (GMNN, CDT1, MCM2 and 7), in reduced expression of the miR-106b cluster (miR-106b, miR-93, and miR-25), and in increased expression of the PTEN tumour suppressor gene. We have shown anti-proliferative effects of enterolactone in earlier stages of prostate disease than previously reported and that these effects are mediated, in part, by microRNA-mediated regulation. View Full-Text
Keywords: enterolactone; lignan; prostate; proliferation; PTEN; miR-106b cluster enterolactone; lignan; prostate; proliferation; PTEN; miR-106b cluster
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

McCann, M.J.; Rowland, I.R.; Roy, N.C. The Anti-Proliferative Effects of Enterolactone in Prostate Cancer Cells: Evidence for the Role of DNA Licencing Genes, mi-R106b Cluster Expression, and PTEN Dosage. Nutrients 2014, 6, 4839-4855.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top